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Abstract
Background: Acetylcholinesterase inhibitors cannot rapidly reverse profound neuromuscular block. Sugammadex, a
selective relaxant binding agent, reverses the effects of rocuronium and vecuronium by encapsulation. This study
assessed the efficacy of sugammadex compared with neostigmine in reversal of profound vecuronium-induced
neuromuscular block under sevoflurane anesthesia.
Methods: Patients aged ≥18 years, American Society of Anesthesiologists class 1-4, scheduled to undergo surgery
under general anesthesia were enrolled in this phase III, multicenter, randomized, safety-assessor blinded study.
Sevoflurane anesthetized patients received vecuronium 0.1 mg/kg for intubation, with maintenance doses of 0.015
mg/kg as required. Patients were randomized to receive sugammadex 4 mg/kg or neostigmine 70 μg/kg with
glycopyrrolate 14 μg/kg at 1-2 post-tetanic counts. The primary efficacy variable was time from start of study drug
administration to recovery of the train-of-four ratio to 0.9. Safety assessments included physical examination,
laboratory data, vital signs, and adverse events.
Results: Eighty three patients were included in the intent-to-treat population (sugammadex, n = 47; neostigmine,
n = 36). Geometric mean time to recovery of the train-of-four ratio to 0.9 was 15-fold faster with sugammadex
(4.5 minutes) compared with neostigmine (66.2 minutes; p < 0.0001) (median, 3.3 minutes with sugammadex
versus 49.9 minutes with neostigmine). No serious drug-related adverse events occurred in either group.
Conclusions: Recovery from profound vecuronium-induced block is significantly faster with sugammadex,
compared with neostigmine. Neostigmine did not rapidly reverse profound neuromuscular block (Trial registration
number: NCT00473694).
Background
In some types of surgery, including many ENT, thoracic,
abdominal and neurosurgical procedures, performed
under general anesthesia, maintenance of profound
relaxation throughout the procedure may be beneficial.
However, anesthesiologists are limited in their capacity
to provide such levels of neuromuscular block towards
the end of surgery in particular, because the traditional
agents available for the reversal of neuromuscular block
(acetylcholinesterase inhibitors) cannot rapidly reverse
profound block [1]. This is especially important if vola-
tile anesthetics have been used as they are known to
potentiate the blocking effect of the neuromuscular
blocking agents and impair reversal by the acetylcholi-
nesterase inhibitors [2].
Sugammadex is a new selective relaxant binding agent.
Previously, sugammadex has been shown to effectively
reverse profound block induced by rocuronium 0.6-1.2
mg/kg, with times from administration of sugammadex
to a train-of-four (TOF) ratio >0.9 in the region of 2-3
minutes [3-5]. Vecuronium, a non-depolarizing neuro-
muscular blocking agent with a greater potency than
rocuronium [6], has the same basic steroid nucleus
structure as rocuronium. To date, a single dose-finding
study has examined the efficacy of sugammadex to
reverse profound block induced by vecuronium [3].
The present phase III study was the first to examine
the efficacy and safety of sugammadex compared with
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block induced by vecuronium. This study consisted of
two arms, and also assessed the efficacy and safety of
sugammadex compared with neostigmine in the reversal
of profound rocuronium block; the two parts of
the study were separately powered. Here, we describe
the results for the vecuronium arm only and results for
the rocuronium arm have been reported separately [5].
Methods
This was a multicenter, randomized, parallel-group,
safety-assessor blinded, phase IIIA trial, designated the
Signal study (NCT00473694). Patients were allocated to
one of four treatment groups in sequence of their
enrollment (rocuronium or vecuronium neuromuscular
blocking agent and sugammadex or neostigmine for
reversal) using a computer-generated randomization
schedule prepared centrally by the study sponsor. Only
the safety assessor was blinded to study treatment.
Thus, drugs were prepared by an investigator who was
not involved in the safety assessments.
Patients
Adults aged ≥18 years, American Society of Anesthesiol-
ogists class 1-4 who were scheduled to undergo elective
surgery in the supine position under general anesthesia
requiring the use of a neuromuscular blocking agent for
tracheal intubation and maintenance of neuromuscular
block were eligible for enrollment in this study. Patients
were excluded if they had a neuromuscular disorder; a
history of malignant hyperthermia; significant renal dys-
f u n c t i o n ;a na l l e r g yt on a r c o tics, muscle relaxants, or
other medication used during general anesthesia; were
using medication known to interfere with neuromuscu-
lar blocking agents (e.g., antibiotics, anticonvulsants, and
magnesium); or were pregnant, breast feeding, or of
childbearing potential and not using an adequate
method of contraception.
The study protocol was approved by the Independent
Ethics Committee of each trial center and the study was
conducted in compliance with the current revision of
the Declaration of Helsinki, the International Confer-
ence on Harmonization guidelines, Good Clinical Prac-
tice, and current regulatory requirements. All patients
provided written informed consent.
Anesthesia and neuromuscular block
Anesthesia was induced with an intravenous opioid and
intravenous propofol, and maintained with an intrave-
nous opioid and sevoflurane. The recommended sevo-
flurane concentration was <1.5 times the age-adjusted
minimum alveolar concentration at the time of sugam-
madex or neostigmine administration. A single intrave-
nous bolus dose of vecuronium 0.1 mg/kg was
administered within 10 seconds into a fast-running
venous infusion. Neuromuscular block was maintained
with 0.015 mg/kg doses of vecuronium as required.
Neuromuscular function was monitored by accelero-
myography at the adductor pollicis muscle using the
TOF-Watch® SX (Organon Ireland Ltd, a division of
M e r c ka n dC o ,I n c ,S w o r d s ,C o .D u b l i n ,I r e l a n d ) .A f t e r
induction of anesthesia, the TOF-Watch® SX was affixed
to the arm that had the intravenous cannula for drug
administration, and stabilized and calibrated in the oper-
ating room. The investigators used a standard method
to set up and monitor responses using the TOF-Watch®
SX, in order to minimize trial center variability.
Repetitive TOF stimulation was applied every 15 sec-
onds at the ulnar nerve until the end of anesthesia or at
least until recovery of the TOF ratio to 0.9. Neuromus-
cular data were collected via a transducer fixed to the
volar aspect of the distal phalanx of the thumb. When
the first twitch response from the TOF stimulation
mode had disappeared after the intubation dose, post-
tetanic count (PTC) stimulation was started by deliver-
ing a 5-sec, 50 Hz tetanic stimulation, followed after by
a 3-sec pause, by applying stimulations at a frequency of
1 Hz for 15 sec and the cycle repeated every 6 min until
a PTC of 1 or 2 was achieved. The TOF-Watch® SX
automatically prevented the use of the PTC button for 2
minutes after a previous PTC. When considered appro-
priate by the attending anesthesiologist, spontaneous
recovery of neuromuscular function was permitted after
the last dose of vecuronium until a target of 1-2 PTC
was reached, at which point patients were reversed with
either a single bolus dose of sugammadex 4 mg/kg or
neostigmine 70 μg/kg with glycopyrrolate 14 μg/kg.
Neuromuscular monitoring was switched to the TOF
mode as described above and continued until the end of
anesthesia at least until recovery of the TOF ratio to
0.9, considered sufficient for safe extubation.
Peripheral body temperature was measured continu-
ously by a thermister at the thenar eminence of the
palm, and was kept constant at 32°C during the neuro-
muscular monitoring process. Central body temperature
was maintained continuously at ≥35°C.
Patients were not permitted to receive any muscle
relaxant other than vecuronium, or a second dose of
sugammadex or any other reversal agent other than
neostigmine during the monitoring of neuromuscular
transmission. If further muscle relaxation was required
after the administration of sugammadex, a non-steroidal
muscle relaxant could be administered.
Assessment of safety
Patients were assessed for consciousness after admission
to the recovery room; if they were fully awake and
oriented and considered cooperative, 5-second head-lift
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a blinded safety assessor. Tests were repeated every
15 minutes until the patient could successfully perform
the 5-second head-lift and again before transfer from
the recovery room. The assessment of general muscle
weakness was based on a scale from 0-10, with 0 repre-
senting total paralysis, 1 signifying extreme impairment,
9 for close to no impairment, and 10 for normal muscle
strength. Scores of 3, 4, 5, etc. denoted increasing mus-
cle strength in approximately 10% increments [5].
Patients who had not reached a TOF ratio of 0.9
before transfer to the recovery room remained intu-
bated, sedated, and ventilated until recovery to a TOF
ratio of 0.9, and patients with any evidence of residual
neuromuscular block, such as respiratory symptoms,
after extubation were maintained with adequate ventila-
tion, using measures such as correction of electrolyte
abnormalities, keeping the subject warm, airway support
including supplemental oxygen, and prompt review of
possible etiologic factors contributing to prolonged neu-
romuscular block. Patients were also assessed for evi-
dence of reoccurrence of block after initial recovery
either by continued monitoring of the TOF trace (look-
ing for a decrease in the TOF ratio to < 0.8) in patients
who had not awakened or by presence of respiratory
symptoms.
Adequacy of spontaneous ventilation, measured by
pulse oximetry and respiratory rate, was assessed for at
least 60 minutes after recovery of the TOF ratio to 0.9.
Blood samples were collected before the administration
of vecuronium, 4-6 hours after reversal agent adminis-
tration, and at the post-anesthetic visit for biochemistry
and full blood count. Urine samples were collected
24 hours before surgery and at the post-anesthetic visit.
A physical examination was performed by the blinded
safety assessor at screening and at the post-anesthetic
visit. Vital signs (blood pressure and heart rate) were
assessed at screening, before the administration of
vecuronium, before the administration of study drug, at
2, 5, and 10 minutes after, and at the post-anesthetic
visit.
All adverse events (AEs), serious AEs, laboratory data,
and vital signs were recorded for the safety analysis. AEs
were assessed by a safety assessor blinded to treatment
randomization. All AEs and serious AEs were coded
using MedDRA (International Federation of Pharmaceu-
tical Manufacturers and Associations, Chantilly, Virginia,
US) version 9.1.
Statistical analysis
The standard deviation of time to recovery of the TOF
ratio to 0.9 was assumed to be 1.5 minutes with sugam-
madex and 7.0 minutes with neostigmine. Based on this,
as a m p l es i z eo f3 0p a t i e n t sp e rg r o u pw o u l dh a v ea
95% probability of detecting a difference of 5 minutes in
t h et i m et or e c o v e r yo ft h eT O Fr a t i ot o0 . 9 .A s s u m i n g
a 5% drop-out rate, 32 patients per group would be
needed. In order to distribute enrollment evenly over
nine trial sites, the intended sample size was 36 patients
per group. The statistical analyses performed in this
study have been reported previously for the rocuronium
arm of the study [5].
Efficacy analyses
Data are presented as geometric means and medians
with overall and interquartile ranges. The primary effi-
cacy variable was time from start of administration of
sugammadex or neostigmine to recovery of the TOF
ratio to 0.9. A two-way analysis of variance was used to
detect the treatment effect, the center effect and the
interaction effect. If an interaction effect was found to
exist, the treatment effect for each center was examined
individually. If no interaction effect was present, an
additive model (without interaction) effect was analyzed.
Secondary efficacy variables included the time from the
start of administration of sugammadex or neostigmine
to recovery of the TOF ratio to 0.8 and 0.7, and clinical
signs of recovery assessed before transfer to the recovery
room and before discharge from the recovery room (as
described above).
Efficacy analyses were based on the intent-to-treat
population, which included all the patients who received
study drug and had at least one efficacy assessment. The
all-subjects-treated group, which consisted of all the
subjects who were randomized, and received a dose of
study medication, was used for the safety analysis.
In order to include all patients from the intent-to-treat
population, missing data for the primary parameter of
time to a TOF ratio of 0.9 were imputed. For imputa-
tion of missing times from the start of administration of
study drug to recovery of the TOF ratio to 0.7, 0.8, and/
or 0.9, a conservative approach towards sugammadex
was applied (described in detail elsewhere) [5]. For
example, when time to a TOF ratio of 0.8 was available,
the difference between the time to recovery of the TOF
ratio to 0.8 and 0.9 for all patients randomized to
sugammadex with available data was calculated. The
95th percentile of these differences was then added to
t h et i m et or e c o v e r yo ft h eT O Fr a t i ot o0 . 8f o rt h o s e
patients with missing times to recovery of the TOF ratio
to 0.9. The same method was used for the neostigmine
group, but available data from patients randomized to
n e o s t i g m i n ew e r ei n c l u d e da nd the fifth percentile of
the differences in time to recovery of the TOF ratio to
0.8 and 0.9 was used to impute missing data.
An interim analysis of efficacy was performed when
10 patients from each group had completed the study
and provided data. The Hwang-Shih-de Cani method
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parameter using validated data for the intent-to-treat
population, with imputed data utilized in the case of
missing values [7]. The interim analysis was conducted
at a significance level of 0.0025 (one-sided), and the
results analysis assessed by a Data and Safety Monitor-
ing Board who were to make a recommendation to stop
the neostigmine arm early if there were marked differ-
ences in efficacy between treatment arms. Enrollment
continued into both groups during the data analysis and
deliberations of the Data and Safety Monitoring Board.
Because of the interim analysis, the primary analysis of
the study was performed at a significance level of
0.0467.
Results
Patients
A total of 94 patients (52 to sugammadex and 42 to neos-
tigmine) were randomized at eight centers in the US
(Stanford University Medical Center, Stanford, California;
Advocate Illinois Masonic Medical Center, Chicago,
Illinois; Vanderbilt University Medical Center, Nashville,
Tennessee; Duke University Medical Center, Durham,
North Carolina; Saddleback Memorial Medical Center,
Laguna Hills, California; The State University of New York
at Stony Brook, Health Sciences Center, Stony Brook, New
Y o r k ;M a y oC l i n i c ,S tL u k e ’s Hospital, Jacksonville,
Florida; University of California, San Francisco, Moffitt/
Long Hospital and Mount Zion Hospital, San Francisco,
California). After interim analysis, and recommendation
by the Data and Safety Monitoring Board, the neostigmine
group was discontinued because of marked differences in
efficacy between treatments, although by this time 42
patients had already been randomized into the neostig-
mine group. A total of 11 patients (five sugammadex and
six neostigmine) discontinued the trial before receiving the
study drug. In addition, one patient randomized to vecuro-
nium and sugammadex received rocuronium plus neostig-
mine and was excluded from the all-subjects-treated
population, but was included in the intent-to-treat popula-
tion according to randomization schedule (Figure 1).
Therefore, the all-subjects-treated population consisted of
46 patients treated with sugammadex and 36 patients trea-
ted with neostigmine, and the intent-to-treat population
consisted of 47 patients randomized to sugammadex and
36 patients randomized to neostigmine. Patients under-
went varied surgical procedures, with the most common
being gynecologic (37.8%), urologic (31.7%), open abdom-
inal (9.8%), and laparoscopic abdominal (9.8%). Baseline
characteristics were comparable between groups, except
that the sugammadex group included more women (63%
versus 42%), more patients who were American Society of
Anesthesiologists class 1-2 (87% versus 64%), and had a
younger mean age (50 versus 57 years) (Table 1).
Anesthesia and neuromuscular block
G e n e r a l l y ,t h eg r o u p sw e r es i m i l a ri nt h ea n e s t h e t i c
agents administered. In total, 91% of sugammadex
patients and 94% of neostigmine patients received sevo-
flurane maintenance anesthesia, with most patients
receiving a range of sevoflurane concentrations over the
course of anesthesia. In the sugammadex group as a
whole, the sevoflurane end-tidal concentration ranged
overall from 0.5-4.2% in the period before sugammadex
administration and from 2.4-0.2% in the period after
sugammadex administration. The corresponding concen-
trations in the neostigmine group overall were 0.3-4.0%
before and 3.5-0.1% after neostigmine. The duration of
sevoflurane exposure in the sugammadex group ranged
from 14 minutes to 6.0 hours before sugammadex, and
from 1 minute to 3.9 hours after sugammadex. The dura-
tions of sevoflurane exposure in the neostigmine group
ranged from 45 minutes to 3.8 hours before and from
17 minutes to 5.2 hours after neostigmine. Four patients
in the sugammadex group did not receive sevoflurane;
three of these received isoflurane rather than sevoflurane
(concentration ranging from 0.7-4.0% overall) and one
patient received no maintenance anesthesia. In addition,
in one sugammadex patient, sevoflurane was stopped
after 14 minutes and desflurane (6-6.5%) administered
instead. Two patients in the neostigmine group did not
receive sevoflurane. They received isoflurane (0.3-0.9%)
or desflurane (3.7-8.0%) instead. The inhalation anes-
thetic was maintained at least until recovery of the TOF
ratio to 0.9 in 75% of patients in the two groups (deter-
mined in those patients in whom the time to a TOF ratio
of 0.9 was known and the time of anesthetic discontinua-
tion was recorded [n = 64]). Nitrous oxide was adminis-
tered to 52% of patients in the sugammadex group and
56% of patients in the neostigmine group.
Forty-two sugammadex- and 32 neostigmine-treated
patients received at least one maintenance dose of
vecuronium. In patients receiving maintenance doses, a
median of four (range 1-20) maintenance doses were
administered in the sugammadex group and a median of
two (range 1-12) maintenance doses were administered
in the neostigmine group. In accordance with the proto-
col, in most patients (83% in the sugammadex group
and 75% in the neostigmine group), the reversal drug
was administered at a PTC of 1 or 2 after the last dose
of vecuronium, although 7 patients in the sugammadex
group and 9 patients in the neostigmine group received
reversal at a higher PTC, including one patient who
received neostigmine at a PTC of 6, which was consid-
ered to be a protocol violation. The median (range) time
between administration of the last dose of vecuronium
and administration of the reversal agent was 19.7 (3.4 to
102.7) minutes in the sugammadex group and 15.5 (3.2
to 112.4) minutes in the neostigmine group.
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Four subjects in the sugammadex intent-to-treat group
(including the patient who received rocuronium and
neostigmine in error), and 19 in the neostigmine group
h a dm i s s i n gd a t af o rt i m et or e c o v e r yo ft h eT O Fr a t i o
to 0.9. In three of the sugammadex patients and ten of
the neostigmine patients, the TOF-Watch had to be
switched off before this level of recovery was reached; in
one sugammadex patient, the time to TOF 0.9 was
omitted from the assessments; and in the remaining
nine neostigmine patients, the patient was moving or
awake before a TOF ratio of 0.9 was reached. In addi-
tion, the Central Independent Adjudication Committee
considered the time to the TOF ratio of 0.9 to be unreli-
able in two subjects from each group because of inter-
ference, an unstable recording or because of an
incorrect set-up procedure of the TOF-Watch. Thus
recovery data were imputed for these patients.
Figure 2 shows representative examples of the recov-
ery profile from neuromuscular block after sugammadex
and neostigmine administration. Geometric mean time
to recovery of the TOF ratio to 0.9 was significantly
Figure 1 Patient disposition. One patient randomized to sugammadex/vecuronium was mistakenly given neostigmine/rocuronium and
excluded from the AST population, but included in the ITT population according to the proposed randomization.*Data for patients randomized
to the rocuronium arm have been reported elsewhere [5]. AST, all-subjects-treated; ITT, intent-to-treat; TOF, train-of-four.
Table 1 Baseline characteristics (all-subjects-treated
population [n = 82])
Sugammadex (n = 46) Neostigmine (n = 36)
Gender
Female, n (%) 29 (63) 15 (42)
Male, n (%) 17 (37) 21 (58)
Mean (SD) age, years 50 (14) 57 (12)
Mean (SD) weight, kg 86 (19) 86 (18)
Mean (SD) height, cm 170 (11) 173 (10)
Race, n (%)
Asian 1 (2) 3 (8)
Black (of African
heritage)
6 (13) 1 (3)
Caucasian 38 (83) 32 (89)
Other 1 (2) 0
ASA class, n (%)
1 6 (13) 1 (3)
2 34 (74) 22 (61)
3 6 (13) 13 (36)
40 0
ASA, American Society of Anesthesiologists.
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(4.5 minutes versus 66.2 minutes, p < 0.0001) (Table 2).
The median (range [interquartile range] time to recovery
of the TOF ratio to 0.9 was 3.3 (1.4-68.4 [2.3-6.6]) min-
utes in the sugammadex group versus 49.9 (46.0-312.7
[46.0-96.6]) in the neostigmine group. The faster time to
recovery in the sugammadex group is also shown in
Figure 3, which compares the cumulative percentage of
patients who recovered to a TOF ratio of 0.9 over the
course of the study in sugammadex and neostigmine
groups, versus time after administration of the study
drug. In a separate analysis including only those patients
with data available for the time to TOF 0.9 (n = 41 in
the sugammadex group and n = 15 in the neostigmine
group), the geometric mean recovery times were 3.6
minutes versus 91 minutes, respectively (p < 0.0001).
The geometric mean times to recovery of the TOF ratio
to 0.7 and 0.8 were also significantly faster with sugam-
madex compared with neostigmine (p < 0.0001) (Table
2). The patient who was randomized to vecuronium and
sugammadex but received rocuronium and neostigmine
in error had no data available for the times to a TOF
r a t i oo f0 . 8a n d0 . 9 .H e rt i m ef r o ms t u d yd r u ga d m i n i s -
tration to a TOF ratio of 0.7 was 61.9 minutes and her
imputed times to a TOF ratio of 0.8 and 0.9 were 65.2
and 68.4 minutes, respectively. Thus, these were the
longest times to recovery in each case (Table 2). Two
other patients in the sugammadex group also had rela-
tively long times to a TOF ratio of 0.9 of 47.4 and
63.5 minutes. In these patients, the times to a TOF ratio
of 0.7 were 2.9 and 7.3 minutes, respectively. In the first
of these two patients, the investigator reported difficulties
in calibrating, and commencement of tracing prior to
adequate baseline TOF values being established.
In the sugammadex group, most patients (n = 44)
received an intubating dose plus one or more mainte-
nance doses of vecuronium. Geometric mean time to
reversal of vecuronium-induced block appeared to be
similar in patients who received at least one mainte-
nance dose of vecuronium compared with those patients
who received an intubating dose only (4.5 versus
4.2 minutes).
Figure 2 Examples of recovery profiles for vecuronium 0.1 mg/kg after administration of (A) sugammadex 4 mg/kg or (B) neostigmine
70 μg/kg at a target of 1-2 PTC. Bars represent first twitch (T1) values (twitch height %) and dots represent the TOF ratio. PTC, post-
tetanic-counts; TOF, train-of-four.
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Except for nine patients in the sugammadex group and
10 patients in the neostigmine group, the majority of
patients were considered cooperative before transfer to
the recovery room, allowing the 5-second head-lift and
general muscle weakness tests to be performed. In those
patients with assessments before discharge from the
recovery room (n = 41 in the sugammadex group and
n = 34 in the neostigmine group), all except two
patients in the sugammadex group and one in the neos-
tigmine group were awake and oriented, all patients
were considered cooperative, and all patients, except for
one in the neostigmine group, were able to perform the
5-second head-lift. Of the 41 sugammadex patients and
34 neostigmine patients with assessments, four patients
showed signs of mild general muscle weakness, as
assessed by the general muscle weakness scale, before
discharge from the recovery room, (sugammadex, n = 1
[score of 8]; neostigmine, n = 3 [scores of 7, 8, and 8])
but all affected patients could perform the 5-second
head-lift test before discharge from the recovery room.
Safety assessments
In the all-subjects-treated group, all patients in the sugam-
madex group and 33 patients in the neostigmine group
(92%) had at least one AE. Table 3 shows AEs occurring
in ≥10% of patients in either treatment group, regardless
of relationship to study drug. Most AEs were of mild-to-
moderate intensity. The most commonly reported AEs in
both groups were procedural pain and nausea.
Nine patients (19.6%) in the sugammadex group
experienced a total of 18 drug-related AEs and
10 patients (27.8%) in the neostigmine group experi-
enced a total of 21 drug-related AEs. The most
commonly reported drug-related AEs were nausea or
post-procedural nausea (sugammadex, n = 5; neostig-
mine, n = 3) and leukocytosis (sugammadex, n = 1;
neostigmine, n = 2). All of the other drug-related AEs in
both groups were isolated reports and most were of
mild (16/18 in the sugammadex group; 8/21 in the
neostigmine group) or moderate (2/18 in the sugamma-
dex group; 10/21 in the neostigmine group) intensity.
There were only three severe AEs (anxiety, depression,
and fatigue) experienced by a patient in the neostigmine
Table 2 Time to recovery of the train-of-four ratio to 0.9,
0.8, and 0.7.
Sugammadex
(n = 47)
†
Neostigmine
(n = 36)
Time to TOF ratio of 0.9, min
Geometric mean 4.5* 66.2
Median 3.3 49.9
Interquartile range 2.3-6.6 46.0-96.6
Range 1.4-68.4 46.0-312.7
Time to TOF ratio of 0.8, min
Geometric mean 3.3* 58.9
Median 2.7 43.9
Interquartile range 1.8-4.4 42.9-79.8
Range 1.2-65.2 35.3-250.9
Time to TOF ratio of 0.7, min
Geometric mean 2.6* 48.8
Median 2.5 36.4
Interquartile range 1.6-3.3 34.9-67.5
Range 1.1-61.9 27.5-192.2
Recovery times were measured from the start of administration of
sugammadex or neostigmine. Data are given for the intent-to-treat
population, with imputed data.
*p < 0.0001 versus neostigmine.
†Data include the patient who received
rocuronium plus neostigmine reversal rather than vecuronium plus
sugammadex reversal in error, the times to a TOF ratio of 0.9 and 0.8 were
not available. Her times to TOF 0.9 and 0.8 were imputed based on her time
to TOF 0.7 of 61.9 minutes.TOF, train-of-four.
Figure 3 Time (min) from start of administration of
sugammadex or neostigmine to recovery of the TOF ratio to
0.9 (intent-to-treat population, imputed data, n = 47 for
sugammadex and n = 36 for neostigmine). TOF, train-of-four.
Table 3 Adverse events occurring in at least 10% of
patients in either treatment group
Adverse event Sugammadex
(n = 46)
Neostigmine
(n = 36)
Procedural pain 33 (71.7) 24 (66.7)
Nausea 24 (52.2) 12 (33.3)
Incision-site complication 10 (21.7) 8 (22.2)
Pharyngolaryngeal pain 8 (17.4) 7 (19.4)
Headache 12 (26.1) 2 (5.6)
Vomiting 9 (19.6) 4 (11.1)
Dizziness 5 (10.9) 4 (11.1)
Pruritus 5 (10.9) 2 (5.6)
Post-procedural nausea 5 (10.9) 2 (5.6)
Constipation 5 (10.9) 0
Chills 5 (10.9) 0
Adverse events are listed regardless of their perceived relationship to study
drug for the all-subjects-treated population (n = 82).
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drug related. There were no deaths or serious drug-
related AEs in either treatment group.
Laboratory parameters and vital signs were similar
between groups, with the exception of an increase in
mean heart rate from baseline in the neostigmine group
2-10 minutes post dose. However, there were no clini-
cally significant differences between the groups in terms
of the percentage of patients with markedly abnormal
heart rate values at any of the assessments, and mean
heart rate in the neostigmine group returned to baseline
level at subsequent assessment points. There was no
clinical evidence of residual neuromuscular block or
reoccurrence of neuromuscular block either clinically
(respiratory problems) or according to study neuromus-
cular transmission guidelines (significant decrease in the
TOF ratio to <0.8) in either group.
Discussion
This is the first active-controlled study to show that
sugammadex effectively reverses profound vecuronium-
induced block. Recovery from neuromuscular block
induced by vecuronium was almost 15-fold faster with
sugammadex 4 mg/kg than with neostigmine 70 μg/kg
when given at a target of 1-2 PTCs.
There were several missing times to recovery of the
TOF ratio to 0.9 in the study, especially in the neostig-
mine group (19 missing recovery times compared with 4
missing recovery times in the sugammadex group)
resulting from for example patients waking up and mov-
ing so that the TOF trace was not completed. We over-
c a m et h ei s s u eo fm i s s i n gr e c o v e r yt i m e sb yu s i n ga
conservative imputation technique for the primary ana-
lysis, where missing recovery times were estimated using
a worst-case scenario for patients receiving sugammadex
and a best-case scenario for patients receiving neostig-
mine. The geometric mean time to a TOF ratio of 0.9
was 3.6 minutes in the sugammadex group versus 91
minutes in the neostigmine group in an analysis includ-
ing only those patients with a recorded time to TOF 0.9
(n = 41 in the sugammadex group and n = 15 in the
neostigmine group). Thus, using both the conservative
imputation technique and the observed cases only, a
considerably faster time to recovery was seen with
sugammadex 4 mg/kg versus neostigmine at 1-2 PTCs.
One other study, a dose-finding study, has investigated
the efficacy of sugammadex administered during pro-
found vecuronium-induced block (at 1-2 PTCs) [3].
This study showed a mean recovery time of 3.3 minutes
(n = 8) with sugammadex 4 mg/kg [3], consistent with
the current study. Previous reports of the efficacy of
sugammadex in rocuronium-induced profound block
have shown recovery to a TOF ratio of 0.9 in 2-3
minutes [4,5].
In the current study, when considering only those
patients in whom times to TOF 0.9 were available, 80%
had recovered within 5 minutes of sugammadex adminis-
tration. In contrast, no neostigmine patients had recovered
within 5 min, and 36% did not recover to a TOF ratio of
0.9 until >60 minutes after administration of neostigmine
(Figure 3). Three patients receiving sugammadex had a
measured (rather than imputed) time to a TOF ratio of 0.9
of >15 minutes. Time to reversal in these patients was
18.7, 47.4 and 63.5 minutes, respectively. This may reflect
technical difficulties with the TOF-Watch as calibration
data were not adequate prior to start of monitoring, with
unstable individual twitch responses together with
unstable and fluctuating TOF ratio values. At recovery,
significant scatter was observed as unstable twitch
responses and unstable TOF ratio values.
To optimize the reversal achieved with acetylcholines-
terase inhibitors, some spontaneous recovery of neuro-
muscular function is required before administration [8],
and our study confirms this. This means that clinicians
may be unable to maintain profound block to the end of
surgery without the penalty of the time required for
spontaneous recovery prior to acetylcholinesterase inhi-
bitor administration, as well as the fear of residual block
in the recovery room in a patient who has not adequately
recovered from the block. As shown in the current study,
neostigmine is not effective for the rapid reversal of pro-
found vecuronium-induced neuromuscular block, with
the median time to a TOF ratio of 0.9 of 49.9 minutes
and, in fact, one patient took >5 hours to achieve this
level of recovery. Furthermore, 75% of neostigmine
patients recovered to a TOF ratio of 0.9 in ≤96.6 min
while, in the sugammadex group, 75% achieved the same
level of recovery in ≤6.6 min. This suggests increased
predictability of reversal of vecuronium-induced NMB
with sugammadex compared with neostigmine.
It is known that, even with recovery of the TOF ratio to
0.9 or more, muscle weakness from impaired neuromus-
cular transmission can occur [9]. In addition to using the
TOF-Watch, neuromuscular recovery was assessed using
clinical tests (5-sec head-lift test and a test for general
weakness). The 5-second head-lift test may be considered
insensitive [10] and inappropriate for the detection of
residual block [11], and the test for general muscle weak-
ness has not been formally validated and was intended
more as a clinical measurement tool for overall well
being. However, these tests were not meant to stand
alone but rather to complement the findings of the objec-
tive neuromuscular monitoring. On transfer from the
recovery room, all except 2% of patients in the sugamma-
dex group and 9% in the neostigmine group who under-
went these tests had no evidence of muscle weakness and
all but one patient in the neostigmine group could per-
form the 5-second head-lift test.
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flurane can significantly prolong the duration of action
of rocuronium and vecuronium [12,13], and it is well
known that volatile anesthetics can also prolong the
time to reversal with acetylcholinesterase inhibitors [2].
Most of the patients in the current study received main-
tenance anesthesia with sevoflurane, and only one
patient received no inhalation anesthetics. We showed
that sugammadex reversal of profound block was rapid
even in the presence of sevoflurane, isoflurane or des-
flurane. These findings are in agreement with previous
studies, which show sugammadex to be equally effective
at reversing rocuronium-induced block under mainte-
nance anesthesia with sevoflurane or propofol [14,15].
Acetylcholinesterase inhibitors are associated with var-
ious adverse effects related to the increase they cause in
acetylcholine concentration at muscarinic receptors (in
addition to the nicotinic receptors as their intended site
of action), therefore co-administration with an anticholi-
nergic agent such as glycopyrrolate is often required. By
virtue of its mode of action in encapsulating rocuronium
and vecuronium molecules, sugammadex was antici-
pated to be well tolerated [16]. Although our study was
underpowered for many of the safety related issues,
sugammadex was well tolerated, both in the vecuronium
arms described here and in the rocuronium arms of the
study [5]. The most commonly reported AEs in both
groups were procedural pain and nausea. More patients
in the sugammadex group experienced headache, nau-
sea, or vomiting compared with the neostigmine group,
although most of these occurrences were not considered
by the investigator to be related to the study drug. In
total, 20% of sugammadex-treated patients and 28% of
neostigmine-treated patients experienced AEs that were
considered possibly, probably, or definitely related to
study drug. Apart from nausea, most of these were iso-
lated reports and of mild-to-moderate intensity. There
were no serious drug-related AEs in any treatment
group. Many of the tests available for the determination
of mild residual paralysis or reoccurrence of block in
the awake patient have shortcomings. Bearing in mind
this limitation, there was no evidence of residual paraly-
sis or reoccurrence of block found for any patient in
this study.
Conclusions
In conclusion, sugammadex provided effective and rapid
reversal of profound neuromuscular block induced by
vecuronium under sevoflurane anesthesia.
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